- Chiroscience has reported a pretax loss of L4.3 million ($6.45 million) for the 1993/94 fiscal year compared to L1.2 million in 1992/93. Turnover for the year increased from $1.6 million to $1.95 million and research and development expenditure increased to L3.71 million from L1.59 million in 1992/93.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze